Galectin-3 Biomarker Detection for Heart Failure Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods cannot reliably predict the onset of congestive heart failure or its severe complications, and require expensive equipment and trained personnel for diagnosis.
Innovation Solution
A method involving the use of non-myocytical markers, such as galectin-3 and thrombospondin-2, to identify subjects at risk of developing hypertensive end organ damage by measuring marker levels in biological samples and comparing them to standard levels, allowing for early identification and potential prevention of heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used to identify heart failure, then diagnosis can be made, but the methods cannot reliably predict onset or outcome and require expensive equipment and trained personnel
Solution Approach 1:
The patent extracts the predictive function from complex diagnostic equipment and concentrates it in a single biomarker molecule (galectin-3). Instead of using expensive imaging equipment or complex tests, the invention isolates the essential predictive information into a measurable blood parameter that can be detected with simple assays, resolving the contradiction between prediction reliability and equipment complexity
Solution Approach 2:
The patent replaces expensive, complex diagnostic equipment with a simple, inexpensive blood test using galectin-3 measurement. This disposable-like approach (single blood draw) eliminates the need for costly machinery while maintaining or improving predictive reliability, directly addressing the technical contradiction
2Loss of time
If current diagnostic methods are used, then heart failure can be diagnosed, but early identification and prediction of onset cannot be achieved
Solution Approach 1:
The patent enables preliminary identification of heart failure risk by measuring galectin-3 levels before clinical symptoms appear. The biomarker rises in the prodromal phase, allowing early intervention before full-blown heart failure develops, thus gaining critical time without sacrificing prediction reliability
Solution Approach 2:
The patent establishes a feedback mechanism where galectin-3 levels provide continuous information about cardiac stress and failure risk. This biomarker feedback allows clinicians to monitor patients over time, identify trends, and intervene at optimal moments, simultaneously improving early identification capability and prediction reliability
Data Source
AI summary
The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.